Any policy of health insurance delivered, issued for delivery, or renewed in this state, on or after January 1, 2026, must provide coverage for biomarker testing, when ordered by a qualified health care provider operating within the provider's scope of practice, for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition, and when the testing is supported by medical and scientific evidence. For the purposes of this section, the following terms mean: (1) "Biomarker," a characteristic that is objectively measured and evaluated as an indicator of a normal biological process, pathogenic process, or pharmacologic response to a specific therapeutic regimen; and (2) "Biomarker testing," the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker. This section does not apply to policies that provide specified disease or other limited benefit coverage.